Nebenwirkungen · Fintepla
Fintepla 2.2 mg/ml oral solution · Abschnitt 4.8 · PDF-Seite 12
HOS-132992 · Präparat HOS-097342
Gastrointestinal disorders In the Phase 3 LGS controlled trial in children and young adults, diarrhoea (13.1%) and vomiting (10.6%) were observed more frequently in the combined fenfluramine groups than in the placebo group (4.1% and 6.1%, respectively) during the 14-week titration and maintenance periods. In Study 4 the mean time to onset of diarrhoea in the combined fenfluramine groups was 25.4 days versus 46.0 days in the placebo group while the mean time to onset of vomiting in the combined fenfluramine groups was 36.7 days versus 38.2 days in the placebo group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-09T15:00:00Z · SHA-256 e175f94af1e49d4a11fbbc3e861df1256bc1a0a5d612baaf0706babc5f1fc781 · Passage f0f12e96f38854cd9a50b7a3f6dc22971a990fe264ff09fad78de2b1005e0b36 · Zeichen 7619–8191 im Abschnitt